Photogen Announces Encouraging Interim Pilot Study Results Of Treating Psoriasis With PH-10 and Green Light

Apr 25, 2001, 01:00 ET from Photogen Technologies, Inc.

    NEW HOPE, Pa., April 25 /PRNewswire/ --
 Photogen Technologies, Inc. (Nasdaq:   PHGN) today announced interim results of
 a pilot clinical study utilizing its proprietary photoactive drug, PH-10,
 together with green light as a treatment for plaque psoriasis.  In the study,
 psoriatic plaques of patients were sectored so each patient would receive drug
 and light, drug alone, light alone, and no treatment.  Thus each patient acted
 as his or her own control.
     "These interim results, while at an early point, are quite encouraging,"
 said Peter Bjerring, M.D., Dr. Sci. (Med), of the University of Aarhus,
 Denmark who conducted the study.  "PH-10 therapy should be thoroughly studied
 as a potentially important new treatment for this chronic disease."
     "We are very encouraged by the results generated with PH-10," said
 Reinhard Koenig, M.D., Ph.D., Senior Vice President Medical and Regulatory
 Affairs at Photogen.  "Photodynamic therapy, the therapeutic activation of a
 drug by a light source, has long been recognized as a method of treating
 psoriasis.  However, existing therapy often has unacceptable side effects that
 limit treatment.  Because PH-10 is activated with green light, it offers the
 advantage of reducing plaque without the side effects of other agents and
 light sources."
     Plaque sectors receiving both drug and light exhibited a dose dependant
 reduction of plaque of up to 58 percent.  This response is comparable to that
 achieved using topical steroids.  Sectors of plaque receiving drug alone or
 light alone exhibited no statistically significant effect when compared to the
 untreated area.  There were ten patients in the study; all had severe
 psoriasis as measured by standard clinical assessment and high frequency
 ultrasound imaging of plaques.  PH-10 therapy was painless, with no serious
 local or systemic acute side effects, in sharp contrast to most other
 therapeutic options for patients with severe psoriasis.  Responses were
 objectively measured using ultrasound imaging thirty days after a single
 treatment regimen.
     "When PH-10 is applied topically and activated with green light, it is
 believed to selectively reduce inflammation and hyperproliferation of the
 epidermis," said Eric Wachter, Ph.D., Senior Scientist at Photogen.  "This
 appears to result in progressive improvement of symptoms."  PH-10 is a
 proprietary photoactive agent being developed by Photogen as a treatment for
 psoriasis.
 
     Psoriasis is a chronic, recurrent disease of the skin.  It typically
 appears as well defined, dry lesions with large silvery scales and marked
 redness.  Its cause is unknown.  According to the National Psoriasis
 Foundation, psoriasis, of which the most common form is plaque psoriasis,
 affects over seven million people in the U.S.  About 150,000 to 260,000 new
 cases are diagnosed annually.
 
     Photogen develops innovative therapeutic and diagnostic products using
 proprietary drugs and advanced energy sources.  In addition to the use of
 PH-10 as a treatment for psoriasis, it also shows promise as a treatment for
 other topical disorders and for certain cancer tumors.  The company's cancer
 diagnostic, N1177, being developed through a joint venture with Elan
 Corporation, has completed Phase 1 clinical studies.
 
     Statements in this release that are not strictly historical are
 "forward-looking" statements made pursuant to the safe harbor provisions of
 the Private Securities Litigation Reform Act of 1995.  Forward-looking
 statements involve known and unknown risks that may cause Photogen's actual
 results in the future to differ materially from expected results.  These risks
 include the ability of the company: to develop a product and obtain regulatory
 approval for its use, to obtain necessary financing, and to maintain and
 defend intellectual property protection for its proprietary products.  These
 and other risks are described an qualified in their entirety by cautionary
 language and risk factors set forth in the company's filings from time to time
 with the Securities and Exchange Commission.
 
      Contact:
      Brooks Boveroux, CFO
      Photogen Technologies, Inc.
      215-862-6860
 
      Investors - Matthew Orsagh
      Noonan/Russo Communications
      212-696-4455, ext. 357
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X56331351
 
 

SOURCE Photogen Technologies, Inc.
    NEW HOPE, Pa., April 25 /PRNewswire/ --
 Photogen Technologies, Inc. (Nasdaq:   PHGN) today announced interim results of
 a pilot clinical study utilizing its proprietary photoactive drug, PH-10,
 together with green light as a treatment for plaque psoriasis.  In the study,
 psoriatic plaques of patients were sectored so each patient would receive drug
 and light, drug alone, light alone, and no treatment.  Thus each patient acted
 as his or her own control.
     "These interim results, while at an early point, are quite encouraging,"
 said Peter Bjerring, M.D., Dr. Sci. (Med), of the University of Aarhus,
 Denmark who conducted the study.  "PH-10 therapy should be thoroughly studied
 as a potentially important new treatment for this chronic disease."
     "We are very encouraged by the results generated with PH-10," said
 Reinhard Koenig, M.D., Ph.D., Senior Vice President Medical and Regulatory
 Affairs at Photogen.  "Photodynamic therapy, the therapeutic activation of a
 drug by a light source, has long been recognized as a method of treating
 psoriasis.  However, existing therapy often has unacceptable side effects that
 limit treatment.  Because PH-10 is activated with green light, it offers the
 advantage of reducing plaque without the side effects of other agents and
 light sources."
     Plaque sectors receiving both drug and light exhibited a dose dependant
 reduction of plaque of up to 58 percent.  This response is comparable to that
 achieved using topical steroids.  Sectors of plaque receiving drug alone or
 light alone exhibited no statistically significant effect when compared to the
 untreated area.  There were ten patients in the study; all had severe
 psoriasis as measured by standard clinical assessment and high frequency
 ultrasound imaging of plaques.  PH-10 therapy was painless, with no serious
 local or systemic acute side effects, in sharp contrast to most other
 therapeutic options for patients with severe psoriasis.  Responses were
 objectively measured using ultrasound imaging thirty days after a single
 treatment regimen.
     "When PH-10 is applied topically and activated with green light, it is
 believed to selectively reduce inflammation and hyperproliferation of the
 epidermis," said Eric Wachter, Ph.D., Senior Scientist at Photogen.  "This
 appears to result in progressive improvement of symptoms."  PH-10 is a
 proprietary photoactive agent being developed by Photogen as a treatment for
 psoriasis.
 
     Psoriasis is a chronic, recurrent disease of the skin.  It typically
 appears as well defined, dry lesions with large silvery scales and marked
 redness.  Its cause is unknown.  According to the National Psoriasis
 Foundation, psoriasis, of which the most common form is plaque psoriasis,
 affects over seven million people in the U.S.  About 150,000 to 260,000 new
 cases are diagnosed annually.
 
     Photogen develops innovative therapeutic and diagnostic products using
 proprietary drugs and advanced energy sources.  In addition to the use of
 PH-10 as a treatment for psoriasis, it also shows promise as a treatment for
 other topical disorders and for certain cancer tumors.  The company's cancer
 diagnostic, N1177, being developed through a joint venture with Elan
 Corporation, has completed Phase 1 clinical studies.
 
     Statements in this release that are not strictly historical are
 "forward-looking" statements made pursuant to the safe harbor provisions of
 the Private Securities Litigation Reform Act of 1995.  Forward-looking
 statements involve known and unknown risks that may cause Photogen's actual
 results in the future to differ materially from expected results.  These risks
 include the ability of the company: to develop a product and obtain regulatory
 approval for its use, to obtain necessary financing, and to maintain and
 defend intellectual property protection for its proprietary products.  These
 and other risks are described an qualified in their entirety by cautionary
 language and risk factors set forth in the company's filings from time to time
 with the Securities and Exchange Commission.
 
      Contact:
      Brooks Boveroux, CFO
      Photogen Technologies, Inc.
      215-862-6860
 
      Investors - Matthew Orsagh
      Noonan/Russo Communications
      212-696-4455, ext. 357
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X56331351
 
 SOURCE  Photogen Technologies, Inc.